Magnetic resonance imaging (MRI) really makes a difference when studying men who’ve had a negative prostate biopsy, but their prostate-specific antigen goes up overtime or something changes and there’s a continuing concern for prostate cancer, said Christopher Kane, MD, professor of urology, University of California, San Diego.
Magnetic resonance imaging (MRI) really makes a difference when studying men who’ve had a negative prostate biopsy, but their prostate-specific antigen goes up overtime or something changes and we think there’s a continuing concern for prostate cancer, said Christopher Kane, MD, professor of urology, University of California, San Diego.
Transcript (slightly modified)
How is MRI influencing prostate cancer diagnosis?
I think magnetic resonance imaging (MRI) has been 1 of the big changes over the last 5 years. The first place that MRI really makes a difference is in studying men who’ve had previous prostate biopsy, and that biopsy was negative, and overtime their prostate-specific antigen (PSA) goes up or something changes and we think there’s a continuing concern for prostate cancer. Now, we routinely do an MRI before we do a repeat biopsy, and if we see regions that are suspicious for high-grade prostate cancer, we adjust the biopsy to make sure we hit those regions, and that’s called targeted biopsy. That very much improves the outcome of repeat prostate biopsy.
So, we’ve known that and it’s been in our guidelines for more than 5 years, and what’s technology, and now we’re wondering, “Gee, if I have a man and we’re going to recommend a prostate biopsy based on PSA or family history or rectal exam, shouldn’t we do an MRI prior to similarly improve the performance of our biopsy?”
I think many of our programs that are using MRI more liberally are wondering whether we can improve the performance of the initial prostate biopsy by doing an MRI, and that’s an area of controversy not yet in the guidelines. The big controversy is that if we do this is that we’re going to increase costs of the screening episode, and is that justified by the marginal improvement in diagnostics.
That’s the subject of a number of clinical trials. It was the subject of the session this morning. A debate between Professor Emberton and Dr Pedrosa about where is MRI moving, and I think 1 of the places it’s likely moving is earlier, meaning for the initial prostate biopsy.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More